Are Some Genotypes Worse than Others?

[Guest guest]

I know that some genotypes, like 1A which I have, are harder to treat and have a

longer treatment time than others. I've been wondering if some genotypes are

worse to have than others? I remember reading that type 1B had more of an

instance of liver cancer associated with it than others. I hear about people

who don't even know they have it, and I knew right away because I felt like I

had the flu all the time.

WulfeMom

----------

No virus found in this outgoing message.

Checked by AVG Anti-Virus.

Version: 7.0.344 / Virus Database: 267.10.17/84 - Release Date: 8/29/2005

[Guest guest]

That's correct but both 1A and 1B have the same success rate ...about 50%.

Genotype 4 you also treat for 48 weeks but usually responds better tha 1.

Same with 6. Between 2 and 3 , two responds better and 3 is associated with

having steatosis which makes it more difficult than two and also relapses more

than 2.

Silvia

[Guest guest]

Right Sylvia and don't forget the differences in race responses.

African americans have a very poor sustained SVR thru all

genotypes.

[Guest guest]

Let me know if you need more.

Research has shown that it is more effective to treat HCV using a combination

of pegylated interferon and ribavirin than treating without ribavirin. For

people infected with HCV only, SVR is achieved in about 45-50% with genotype 1,

and over 80% with genotype 2 or 3 when treated with the combination.

http://www.atdn.org/simple/pifn.html

The currently acceptable therapy for HCV is a combination of interferon and

ribavirin. Conjugation of polyethylene glycol (PEG) to interferon--pegylated

interferon--is the newest advance in the treatment of HCV patients. Pegylation

increases the elimination half-life of interferon, providing improved efficacy

with once-weekly dosing. SVR rates in patients infected with genotype 1 HCV

have increased from 10-15% with interferon monotherapy to over 50% using the

pegylated interferon-ribavirin combination. Patients infected with genotype 2 or

3 achieve SVR rates of 80% and more.

http://www.vh.org/adult/provider/internalmedicine/hepatitisc/

Pipeline Innovations in Hepatitis C Treatments

However, approximately 50% of patients infected with HCV genotype 1 do not

achieve

a sustained virologic response (SVR) with initial interferon-based ...

www.projectsinknowledge.com/Init/G/1708/ - 83k

May I recommend the Clinicians Guide Volume VII........it's a guide for

doctors to treat Hepatitis C .....all the latest by the best hepatologists in

the

nation.

Silvia

www.projectsinknowledge.com/ init/g/1688/1688_Monograph.pdf

[Guest guest]

Sylvia;

Who told you that 1a & 1b have a 50% sustained

response rate?

I do not believe it is that high. Half of that 50%, I

have read, relapses within two years.

Please give your references.

Thank you.

--- Bhprice425@... wrote:

> That's correct but both 1A and 1B have the same

> success rate ...about 50%.

> Genotype 4 you also treat for 48 weeks but usually

> responds better tha 1.

> Same with 6. Between 2 and 3 , two responds better

> and 3 is associated with

> having steatosis which makes it more difficult than

> two and also relapses more

> than 2.

> Silvia

>

>

> [Non-text portions of this message have been

> removed]

>

>

>

>

[Guest guest]

Look in www.projectsinknowledge.com it's the site with all the experts.

If you are clear 6 months after treatment then you have a 97% chance of

remauining clear......the NIH says so.

After 2 years ...yes I have heard of a few case....rare but they do exist.

There's is one case on recent news that turned out positive after 8 and half

years....

Reemergence of hepatitis C virus after 8.5 years in a patient with

hypogammaglobulinemia: evidence for an occult viral reservoir.

Lee WM, Polson JE, Carney DS, Sahin B, Gale M Jr.

Department of Internal Medicine, Division of Digestive and Liver

Diseases, University of Texas Southwestern Medical Center, Dallas, USA.

The question of whether viruses persist after apparent clearance of

infection remains unanswered. Here, we describe a patient with

hypogammaglobulinemia whose acute hepatitis C virus (HCV) infection

appeared to resolve after receipt of interferon therapy, relapse immediately,

and then clear spontaneously--only to relapse after receipt of corticosteroid

therapy, and clear again, 8.5 years later. Sequencing indicated that the

viruses detected during each relapse were virtually identical, with the

hypervariable region 1 of E2 appearing to be monoclonal, which is typical of

patients

with hypogammaglobulinemia. Nonstructural 5A sequences exhibited quasispecies

diversity initially but, after 8.5 years, had become

monoclonal. The prolonged period of negativity for HCV RNA followed by

relapse suggests that HCV may persist in apparent sustained viral responders.

PMID: 16107964 [PubMed - in process]

[Guest guest]

I need more.

<<If there is no detectable amount of HCV in your

blood six months after you have finished a full course

of treatment, you have a sustained virological

response (SVR).>>

Why don't you research further and find out the stats

for two years after treatment?

Unless, of course, 6 months is all the health duration

you are after.

Selected information is being put out by a company in

who's interest it is to sell a drug treatment. In my

humble opinion, a person who believes that the R & I

companies want to find a cure is naive. A chronic

disease is preferrable to their pockets.

Has anyone heard anything new about VERTEX?

--- Bhprice425@... wrote:

> Let me know if you need more.

>

> Research has shown that it is more effective to

> treat HCV using a combination

> of pegylated interferon and ribavirin than treating

> without ribavirin. For

> people infected with HCV only, SVR is achieved in

> about 45-50% with genotype 1,

> and over 80% with genotype 2 or 3 when treated with

> the combination.

> http://www.atdn.org/simple/pifn.html

>

> The currently acceptable therapy for HCV is a

> combination of interferon and

> ribavirin. Conjugation of polyethylene glycol (PEG)

> to interferon--pegylated

> interferon--is the newest advance in the treatment

> of HCV patients. Pegylation

> increases the elimination half-life of interferon,

> providing improved efficacy

> with once-weekly dosing. SVR rates in patients

> infected with genotype 1 HCV

> have increased from 10-15% with interferon

> monotherapy to over 50% using the

> pegylated interferon-ribavirin combination. Patients

> infected with genotype 2 or

> 3 achieve SVR rates of 80% and more.

>

http://www.vh.org/adult/provider/internalmedicine/hepatitisc/

> Pipeline Innovations in Hepatitis C Treatments

> However, approximately 50% of patients infected with

> HCV genotype 1 do not

> achieve

> a sustained virologic response (SVR) with initial

> interferon-based ...

> www.projectsinknowledge.com/Init/G/1708/ - 83k

> May I recommend the Clinicians Guide Volume

> VII........it's a guide for

> doctors to treat Hepatitis C .....all the latest by

> the best hepatologists in the

> nation.

> Silvia

> www.projectsinknowledge.com/

> init/g/1688/1688_Monograph.pdf

>

>

> [Non-text portions of this message have been

> removed]

>

>

>

>

[Guest guest]

Has anyone heard anything new about VERTEX?

Yea I heard the mice died. Probably will end the research but

we'll see..ric

[Guest guest]

Lol.

You are a snide piece of work. They had 3 week trials

with people.

--- Ric wrote:

>

> Has anyone heard anything new about VERTEX?

> Yea I heard the mice died. Probably will end the

> research but

> we'll see..ric

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>